444 related articles for article (PubMed ID: 15817922)
1. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
[TBL] [Abstract][Full Text] [Related]
2. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
3. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
van der Hoek J; Waaijers M; van Koetsveld PM; Sprij-Mooij D; Feelders RA; Schmid HA; Schoeffter P; Hoyer D; Cervia D; Taylor JE; Culler MD; Lamberts SW; Hofland LJ
Am J Physiol Endocrinol Metab; 2005 Aug; 289(2):E278-87. PubMed ID: 15769796
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
5. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
Batista DL; Zhang X; Gejman R; Ansell PJ; Zhou Y; Johnson SA; Swearingen B; Hedley-Whyte ET; Stratakis CA; Klibanski A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4482-8. PubMed ID: 16940446
[TBL] [Abstract][Full Text] [Related]
6. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
7. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
8. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
9. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
10. Potential indications for somatostatin analogs in Cushing's syndrome.
Arnaldi G; Polenta B; Cardinaletti M; Boscaro M
J Endocrinol Invest; 2005; 28(11 Suppl International):106-10. PubMed ID: 16625858
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
12. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
Nolan LA; Schmid HA; Levy A
Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
14. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
de Bruin C; Pereira AM; Feelders RA; Romijn JA; Roelfsema F; Sprij-Mooij DM; van Aken MO; van der Lelij AJ; de Herder WW; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2009 Apr; 94(4):1118-24. PubMed ID: 19141584
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of β-arrestin1 and β-arrestin2 on somatostatin receptors in murine AtT-20 corticotroph tumor cells.
Kageyama K; Hagiwara R; Niioka K; Takayasu S; Daimon M
Endocr J; 2021 Feb; 68(2):163-170. PubMed ID: 32963176
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
[TBL] [Abstract][Full Text] [Related]
18. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
20. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]